News

The agreement gives Sysmex a non-exclusive right to sell CellaVision’s products in hematology laboratories worldwide. As of April 1, 2010, the non-exclusive agreement comprises all international markets except

The project is being undertaken in collaboration with Sam Gunderson and Rafal Goraczniak at SilaGene (Hillsborough, NJ), a newly formed biotechnology company working on U1 Adapter therapeutics. IDT

In a Phase2 pilot study, Itraconazole topical suspension was shown to be effective in the treatment of FOE with no adverse events reported. Fera Pharma is working to

The partnership calls for SDIX to collaborate with Banyan on the development of antibodies and immuno-solutions that include custom monoclonal and polyclonal antibody development, cell line banking and

Prior to joining Catalent Pharma Mr Booth worked as president and chief operating officer of Medimmune, from 1998 through his retirement in 2003, and as a director from

As per the contract, Astellas is expected to pay EUR25m in three tranches as the steps of transfer of the rights are expected to be concluded over the

Genentech said that the committee’s vote has no effect on the present availability of Avastin for people with advanced HER2-negative breast cancer in the US. The decision on

Biogen Idec posted a net income of $294.6m for the second quarter 2010, or $1.12 per diluted share, compared $144.8m, or $0.49 per diluted share, for the comparable

The drug is the generic equivalent of Sandoz’s reference listed drug (RLD) Phentermine Hydrochloride capsules USP, 30mg. Phentermine Hydrochloride, an appetite suppressant of the amphetamine and phenethylamine class,